Drug Trial Radar · NCT02432144
A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Subjects With Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7)
Last checked: Nov 20, 2026Latest source record: Jul 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Nov 10, 2015
Primary completion
Jan 14, 2019
Study completion Jan 14, 2019
Sponsor
- Lead sponsor
- Ultragenyx Pharmaceutical IncIndustry
- Sponsor type
- Industry
- First posted
- May 1, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the long-term safety of UX003 in subjects with MPS 7.
Conditions
- Sly Syndrome
- MPS VII
- Mucopolysaccharidosis
- Mucopolysaccharidosis VII
Interventions
UX003Drug
solution for intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to DiscontinuationTime frame: From first dose of study drug until 30 days after the last dose of study drug. Mean duration of UX003 treatment was 100.5 weeks.
Locations
7 sites in 4 countries. Site status is shown where the registry gives one.
Children's Hospital Oakland
Oakland, California
Children's Hospital of Orange County
Orange, California
University of Minnesota
Minneapolis, Minnesota
Baylor College of Medicine
Houston, Texas
Hospital Infantil Candido Fontoura Sao Paulo
São Paulo, Brazil
Centenario Hospital Miguel Hidalgo, Pediatrics
Aguascalientes, Mexico
Unidade de Doenças Metabólicas - Centro Hospitalar do Porto
Porto, Portugal
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.